Thursday

8th Dec 2022

EU Commission pushes back on 'slow' vaccine roll-out

  • The second Covid-19 vaccine produced by the US firm Moderna could be approved sometime this week (Photo: Département des Yvelines)

The EU Commission on Monday (4 January) pushed back against criticism that it acquired too few vaccines, causing delays in the roll-out of the anti-Covid-19 jabs in European countries.

The EU executive said it signed six contracts with companies working on vaccines, for two billion doses, in recent months - amid uncertainties which vaccine would be ready and approved first.

Read and decide

Join EUobserver today

Become an expert on Europe

Get instant access to all articles — and 20 years of archives. 14-day free trial.

... or subscribe as a group

Currently, the Pfizer-BioNTech vaccine is the only one authorised in the EU.

The EU agency, the European Medicines Agency (EMA), could approve the vaccine developed by US biotech firm Moderna this week, probably by Wednesday at the latest. The EU has initially secured 80 million Moderna doses, with an option for 80 million more.

The EMA is also waiting for more data on a vaccine from AstraZeneca and Oxford University - which has already been approved in the UK.

A spokesperson for the commission said the aim was to create a diversified portfolio of vaccines.

"We don't put all our eggs in one basket," Stefan De Keersmaecker said, adding that EU leaders also agreed with the policy of not investing in one company, but several, which are working on vaccines.

Under these contracts, the EU has invested both in the development of the vaccines, in research and in capacity-building with various companies - in the hope that it would simplify negotiations and avoid EU member states competing against each other.

Early in the pandemic, France, Germany, Italy, and the Netherlands had already started pooling resources to buy vaccines.

Despite negotiating together under an EU umbrella, member states themselves buy the vaccine doses from the companies directly.

Once a vaccine is considered safe by EMA, member states can place their orders and pay directly, without the commission's involvement.

Delivery also depends on member states, once the doses are produced: it is up to the EU countries and the specific companies to agree on the exact deliveries.

"It is the member states that then decide whether they want to buy the specific vaccine and how many doses, it is not us," commission spokesman Eric Mamer pointed out.

"We could sign contracts for purchase by member states for up to 10bn vaccines but if member states do not buy them, then it serves absolutely no purpose," he added.

The commission said that the roll-out was expected at the end of 2020, and will progressively build up - with big deliveries foreseen for April.

The EU executive also published recommendations in October to member states on how to prepare for a swift vaccination of the population.

The commission also said it is in discussions with Pfizer-BioNTech about the possibility of ordering more doses of their vaccine, in addition to the 300 million shots already covered under existing contracts.

Capacity bottleneck

EU health commissioner Stella Kyriakides said over the weekend that a shortage of production capacity has caused the delays, not EU planning.

"The bottleneck at the moment is not the volume of orders but the worldwide shortage of production capacity," she told DPA, the German news wire.

Ugur Sahin, the co-founder of the German vaccine developer BioNTech, said he is hoping to be able to boost production of their vaccine by February.

He also said in an interview in Der Spiegel magazine on Friday that he had been surprised by the EU's restraint in securing more vaccines from them, saying that the current availability was not looking "rosy".

"We are lacking other approved vaccines and we have to fill this gap with our vaccine," the company founder said.

The commission on Monday did not specifically comment on earlier media reports that in July it had declined an offer of 500 million doses from Pfizer-BioNTech because it was too expensive. The Pfizer-BioNTech vaccine is the second-most expensive.

It also did not comment on German health minister Jens Spahn saying that his country could conduct direct negotiations with German vaccine developers to obtain more doses than under the EU plan.

France has come under specific criticism because it has so far managed only a few hundred doses of vaccines, compared with tens of thousands in Germany and nearly a million in the UK.

Meanwhile, the Netherlands will start its vaccination campaign on Wednesday.

EU faces long wait for full vaccine supplies

The EU is still several months away from having enough vaccines to inoculate its 450 million people, with Pfizer and BioNTech, its principle suppliers, aiming for September for delivery targets.

EU defends its slower vaccine authorisation

After the UK approved the use of the Covid-19 vaccine developed by Pfizer/BioNtech, the pressure is mounting on the EU. But how are these vaccines approved in the bloc - and what is the legal liability?

EU commission keeps vaccine price secret

The European Commission is about to sign a fourth contract for hundreds of millions of vaccine doses against Covid-19. The contracts include non-disclosure clauses, meaning things like price or even where they will be produced remains confidential.

EU leaders to discuss vaccine roll-out this month

EU leaders regularly held video-conferences to coordinate the pandemic reaction last year, but countries and EU institutions recently began a blame-game over the sluggish roll-out of vaccines.

Column

BioNTech: Stop talking about their 'migration background'

I understand that the German-Turkish community - often subjected to condescension in Germany - celebrated the story. Uğur Şahin and Özlem Türecki represent scientific excellence and business success at the highest level.

Opinion

How EU banks underwrote the Qatar World Cup

European banks and investors have invested heavily in Qatari sovereign bonds, and construction and hospitality companies — with scant attention to well-documented human rights violations.

Stakeholders' Highlights

  1. Nordic Council of MinistersLarge Nordic youth delegation at COP15 biodiversity summit in Montreal
  2. Nordic Council of MinistersCOP27: Food systems transformation for climate action
  3. Nordic Council of MinistersThe Nordic Region and the African Union urge the COP27 to talk about gender equality
  4. International Sustainable Finance CentreJoin CEE Sustainable Finance Summit, 15 – 19 May 2023, high-level event for finance & business
  5. Friedrich Naumann Foundation European DialogueGender x Geopolitics: Shaping an Inclusive Foreign Security Policy for Europe
  6. Obama FoundationThe Obama Foundation Opens Applications for its Leaders Program in Europe

Latest News

  1. EU takes legal action against China over Lithuania
  2. EU Commission shoring up children's rights of same-sex parents
  3. The military-industrial complex cashing-in on the Ukraine war
  4. EU delays Hungary funds decision, as Budapest vetoes Ukraine aid
  5. Borrell gets pension from MEP fund set for taxpayer bailout
  6. Autocrats make us all less secure
  7. Big Agri's lies: green EU farming not to blame for food insecurity
  8. German top court declares €800bn EU recovery fund 'legal'

Stakeholders' Highlights

  1. EFBWW – EFBH – FETBBA lot more needs to be done to better protect construction workers from asbestos
  2. European Committee of the RegionsRe-Watch EURegions Week 2022
  3. UNESDA - Soft Drinks EuropeCall for EU action – SMEs in the beverage industry call for fairer access to recycled material
  4. Nordic Council of MinistersNordic prime ministers: “We will deepen co-operation on defence”
  5. EFBWW – EFBH – FETBBConstruction workers can check wages and working conditions in 36 countries
  6. Nordic Council of MinistersNordic and Canadian ministers join forces to combat harmful content online

Join EUobserver

Support quality EU news

Join us